LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

LLY

996.28

-0.56%↓

JNJ

241.82

-0.44%↓

ABBV

228.39

-0.02%↓

NVS

156.11

-3.86%↓

AZN

194.21

-1.63%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

146 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 20:38 UTC

Tulu

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10. märts 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10. märts 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10. märts 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10. märts 2026, 23:06 UTC

Tulu

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10. märts 2026, 22:51 UTC

Uudisväärsed sündmused

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10. märts 2026, 21:21 UTC

Tulu

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10. märts 2026, 21:15 UTC

Tulu

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10. märts 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10. märts 2026, 21:14 UTC

Tulu

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10. märts 2026, 21:13 UTC

Tulu

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q Rev $597.3M >FNV

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q EPS $1.90

10. märts 2026, 20:57 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

10. märts 2026, 20:44 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10. märts 2026, 20:23 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:16 UTC

Tulu

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10. märts 2026, 20:14 UTC

Tulu

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10. märts 2026, 20:14 UTC

Tulu

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10. märts 2026, 20:13 UTC

Tulu

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10. märts 2026, 20:12 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

146 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.